One Company, Two Bets
Altria (MO) and Philip Morris International (PM) were a single company until 2008. The spin-off cut the business in two, and the two halves have been drifting apart ever since.
PM took the international cigarette footprint and, with it, the smoke-free future — the IQOS heated-tobacco and oral-nicotine ramp. MO kept the U.S. cigarette market, the Marlboro trademark inside the United States, and the higher headline yield.
That's the fork the reader actually faces. MO offers a 5.88% trailing yield today. PM offers 3.03% — with a revenue line that has been climbing. (All prices and yields are as of the July 22, 2026 close.) This isn't "one is good and one is bad." It's income-now versus total-return-and-growth, and the numbers below define the tradeoff.
What the one-year chart shows
The total-return chart above complicates the tidy "declining tobacco stock" caricature. Both names have rallied over the trailing year, not sold off. MO sits at $72.17, in the upper part of its $54.70–$75.28 52-week range. PM sits at $194.30, near the top of its $142.11–$199.78 range and up 3.33% on the day.
So the recent window isn't a story of one washed-out name and one obvious bargain. Both have been bid up — and on the one-year chart above, MO actually led on total return (roughly +33% to PM's ~+20%). PM's compounding case leans on the multi-year picture, not this window. The divergence in this piece is about how each fund of cash flow is being returned — yield versus reinvestment and growth — not about one stock being visibly broken.
Performance and yield figures are historical and may change. Total return includes price movement and distributions where available. Past performance does not guarantee future results. Yield is not the same as total return.
How Each One Makes Money
Both are consumer-defensive tobacco businesses with enormous gross margins — MO at 72%, PM at 67% (FY2025) — because cigarettes and nicotine products cost little to produce relative to price.
MO generates nearly all its revenue inside the United States: cigarettes (led by Marlboro), plus oral tobacco (on!), cigars, and a minority stake in Anheuser-Busch InBev. FY2025 revenue was $20.14B. The U.S. cigarette volume trend has been structurally downward for years, which is the central fact hanging over the stock.
PM sells outside the U.S. (and, more recently, is investing back into the U.S. market) with a heavier tilt toward smoke-free products — IQOS and the ZYN oral-nicotine brand. FY2025 revenue was $40.65B. PM's Q2 2026 call reported roughly 10% revenue growth with continued smoke-free gains, per the company's earnings materials.
The strategic distinction: PM is further along the smoke-free exit ramp. Both carry the same secular-decline and regulatory/ESG overhang; PM has simply built more of its revenue around the products meant to outlast combustible cigarettes.
The Dividend: Lead With Cash, Not the Payout Ratio
The earnings payout ratio — about 77% for MO on adjusted EPS (nearer ~100% on GAAP, which the ~$2.1B impairment depressed) and ~76% for PM — is the number screeners lead with. It's the weaker read, because reported earnings for both companies swing on non-cash impairments (MO's Juul and Cronos writedowns are the classic example). The honest safety read is free-cash-flow coverage: cash generated versus cash paid out.
